Valuation: NEOVACS

Market Cap 4.09K 4.71K 3.83K 3.5K 6.6K 448K 6.7K 44.82K 17.58K 225K 17.69K 17.3K 746K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -232K -188K -172K -325K -22.03M -329K -2.2M -864K -11.04M -869K -850K -36.69M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2020-09-30
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 2003-05-27
Director/Board Member - 2020-04-30
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.00% - - 132K
+0.93%-1.43%+1.61%+14.93% 48.57B
+0.26%+9.34%+415.26%+533.80% 41.95B
-1.53%-6.11%+26.37%+7.15% 38.85B
+0.69%+0.79%+7.35%+63.05% 37.24B
+2.47%+8.33%+15.16%+48.37% 30.67B
-0.47%+0.01%+34.08%+126.09% 16.41B
+2.31%-0.87% - - 16.1B
+0.29%+1.81%+4.92%+18.60% 13.97B
-1.43%-9.55%-2.90%-36.38% 12.62B
Average +0.25%-0.30%+62.73%+96.95% 28.48B
Weighted average by Cap. +0.44%+0.39%+82.62%+121.09%

Financials

2023 2024
Net sales 533K 615K 499K 457K 861K 58.47M 874K 5.85M 2.29M 29.3M 2.31M 2.26M 97.37M 434K 500K 406K 372K 701K 47.57M 711K 4.76M 1.87M 23.84M 1.88M 1.84M 79.21M
Net income -8.74M -10.07M -8.19M -7.49M -14.12M -958M -14.33M -95.83M -37.58M -480M -37.82M -36.99M -1.6B -32.91M -37.93M -30.81M -28.19M -53.15M -3.61B -53.94M -361M -141M -1.81B -142M -139M -6.01B
Net Debt -237K -273K -221K -203K -382K -25.93M -388K -2.59M -1.02M -12.99M -1.02M -1M -43.17M -205K -236K -192K -176K -331K -22.48M -336K -2.25M -882K -11.27M -887K -868K -37.44M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
-